Do analysts recommend AVIR or RNTX?

Rein Therapeutics has a consensus price target of $7.00, indicating a potential upside of 586.27%. Given Rein Therapeutics' higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Rein Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, AVIR or RNTX?

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A Rein Therapeutics N/A N/A -$49.87M -$1.90 N/A

Is AVIR or RNTX more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat Rein Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% Rein Therapeutics N/A -510.35% -68.14%

Does the media refer more to AVIR or RNTX?

In the previous week, Rein Therapeutics had 12 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 15 mentions for Rein Therapeutics and 3 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.04 beat Rein Therapeutics' score of 0.98 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rein Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, RNTX or IMRX?

Immuneering is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rein Therapeutics N/A N/A -$49.87M -$1.90 N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is RNTX or IMRX more profitable?

Immuneering's return on equity of -31.93% beat Rein Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rein Therapeutics N/A -510.35% -68.14% Immuneering N/A -31.93% -29.92%

Does the media prefer RNTX or IMRX?

In the previous week, Rein Therapeutics had 10 more articles in the media than Immuneering. MarketBeat recorded 15 mentions for Rein Therapeutics and 5 mentions for Immuneering. Rein Therapeutics' average media sentiment score of 0.98 beat Immuneering's score of 0.07 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is RNTX or PALI more profitable?

Palisade Bio's return on equity of -36.79% beat Rein Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rein Therapeutics N/A -510.35% -68.14% Palisade Bio N/A -36.79% -34.34%

Does the media favor RNTX or PALI?

In the previous week, Rein Therapeutics had 13 more articles in the media than Palisade Bio. MarketBeat recorded 15 mentions for Rein Therapeutics and 2 mentions for Palisade Bio. Rein Therapeutics' average media sentiment score of 0.98 beat Palisade Bio's score of 0.63 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palisade Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RNTX or PBYI?

Rein Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 586.27%. Given Rein Therapeutics' higher possible upside, research analysts plainly believe Rein Therapeutics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rein Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, RNTX or GLSI?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rein Therapeutics N/A N/A -$49.87M -$1.90 N/A Greenwich LifeSciences N/A N/A -$15.79M -$1.46 N/A

Is RNTX or GLSI more profitable?

Rein Therapeutics' return on equity of -510.35% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets Rein Therapeutics N/A -510.35% -68.14% Greenwich LifeSciences N/A -1,042.84% -565.43%

Does the media prefer RNTX or GLSI?

In the previous week, Rein Therapeutics had 9 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 15 mentions for Rein Therapeutics and 6 mentions for Greenwich LifeSciences. Rein Therapeutics' average media sentiment score of 0.98 beat Greenwich LifeSciences' score of -0.07 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Greenwich LifeSciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Rein Therapeutics (RNTX) Competitors

$1.02 -0.01 (-0.97%)

Closing price 04:00 PM Eastern

Extended Trading

$1.03 +0.01 (+0.98%)

As of 07:02 PM Eastern

Compare

RNTX vs. AVIR, IMRX, PALI, PBYI, and GLSI

Should you buy Rein Therapeutics stock or one of its competitors? MarketBeat compares Rein Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rein Therapeutics include Atea Pharmaceuticals (AVIR), Immuneering (IMRX), Palisade Bio (PALI), Puma Biotechnology (PBYI), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry.

How does Rein Therapeutics compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

Atea Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A

Atea Pharmaceuticals' return on equity of -57.01% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Rein Therapeutics	N/A	-510.35%	-68.14%

86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Rein Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Rein Therapeutics has a consensus price target of $7.00, indicating a potential upside of 586.27%. Given Rein Therapeutics' higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Rein Therapeutics had 12 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 15 mentions for Rein Therapeutics and 3 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.04 beat Rein Therapeutics' score of 0.98 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rein Therapeutics beats Atea Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Rein Therapeutics compare to Immuneering?

Rein Therapeutics (NASDAQ:RNTX) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Rein Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

In the previous week, Rein Therapeutics had 10 more articles in the media than Immuneering. MarketBeat recorded 15 mentions for Rein Therapeutics and 5 mentions for Immuneering. Rein Therapeutics' average media sentiment score of 0.98 beat Immuneering's score of 0.07 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Immuneering is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Rein Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 586.27%. Immuneering has a consensus price target of $16.50, suggesting a potential upside of 262.64%. Given Rein Therapeutics' higher possible upside, equities research analysts clearly believe Rein Therapeutics is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Immuneering's return on equity of -31.93% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-510.35%	-68.14%
Immuneering	N/A	-31.93%	-29.92%

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 5.1% of Rein Therapeutics shares are held by insiders. Comparatively, 22.9% of Immuneering shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Rein Therapeutics and Immuneering tied by winning 7 of the 14 factors compared between the two stocks.

How does Rein Therapeutics compare to Palisade Bio?

Rein Therapeutics (NASDAQ:RNTX) and Palisade Bio (NASDAQ:PALI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Rein Therapeutics currently has a consensus target price of $7.00, suggesting a potential upside of 586.27%. Palisade Bio has a consensus target price of $10.20, suggesting a potential upside of 428.50%. Given Rein Therapeutics' higher probable upside, research analysts plainly believe Rein Therapeutics is more favorable than Palisade Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Rein Therapeutics had 13 more articles in the media than Palisade Bio. MarketBeat recorded 15 mentions for Rein Therapeutics and 2 mentions for Palisade Bio. Rein Therapeutics' average media sentiment score of 0.98 beat Palisade Bio's score of 0.63 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palisade Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio's return on equity of -36.79% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-510.35%	-68.14%
Palisade Bio	N/A	-36.79%	-34.34%

Palisade Bio has higher revenue and earnings than Rein Therapeutics. Palisade Bio is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A
Palisade Bio	$250K	1,340.04	-$16.78M	-$1.01	N/A

Rein Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 11.8% of Palisade Bio shares are held by institutional investors. 5.1% of Rein Therapeutics shares are held by insiders. Comparatively, 0.1% of Palisade Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Palisade Bio beats Rein Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to Puma Biotechnology?

Rein Therapeutics (NASDAQ:RNTX) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Puma Biotechnology has higher revenue and earnings than Rein Therapeutics. Rein Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A
Puma Biotechnology	$228.40M	1.52	$31.11M	$0.48	14.19

In the previous week, Rein Therapeutics had 14 more articles in the media than Puma Biotechnology. MarketBeat recorded 15 mentions for Rein Therapeutics and 1 mentions for Puma Biotechnology. Rein Therapeutics' average media sentiment score of 0.98 beat Puma Biotechnology's score of 0.94 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Rein Therapeutics	Positive
Puma Biotechnology	Positive

Rein Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 586.27%. Given Rein Therapeutics' higher possible upside, research analysts plainly believe Rein Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Puma Biotechnology has a net margin of 10.69% compared to Rein Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-510.35%	-68.14%
Puma Biotechnology	10.69%	20.30%	12.05%

Rein Therapeutics has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by insiders. Comparatively, 22.2% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Puma Biotechnology beats Rein Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Rein Therapeutics compare to Greenwich LifeSciences?

Rein Therapeutics (NASDAQ:RNTX) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Rein Therapeutics' return on equity of -510.35% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-510.35%	-68.14%
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Rein Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 586.27%. Greenwich LifeSciences has a consensus target price of $47.50, suggesting a potential upside of 95.55%. Given Rein Therapeutics' higher probable upside, research analysts clearly believe Rein Therapeutics is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rein Therapeutics has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A

In the previous week, Rein Therapeutics had 9 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 15 mentions for Rein Therapeutics and 6 mentions for Greenwich LifeSciences. Rein Therapeutics' average media sentiment score of 0.98 beat Greenwich LifeSciences' score of -0.07 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Greenwich LifeSciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Rein Therapeutics beats Greenwich LifeSciences on 7 of the 13 factors compared between the two stocks.

Get Rein Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNTX vs. The Competition

Export

Metric	Rein Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$87.25M	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	-0.54	17.93	22.30	24.19
Price / Sales	N/A	324.62	581.44	138.36
Price / Cash	18.71	116.27	42.31	57.88
Price / Book	-0.95	6.63	9.84	6.72
Net Income	-$49.87M	$24.20M	$3.57B	$337.19M
7 Day Performance	-3.77%	-3.24%	-1.16%	0.48%
1 Month Performance	-0.97%	0.53%	3.85%	5.07%
1 Year Performance	-49.50%	47.24%	27.40%	34.25%

Rein Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNTX Rein Therapeutics	4.1894 of 5 stars	$1.02 -1.0%	$7.00 +586.3%	-46.6%	$87.25M	N/A	N/A	9	Analyst Forecast Short Interest Decrease Analyst Revision
AVIR Atea Pharmaceuticals	1.0073 of 5 stars	$4.67 flat	N/A	+37.7%	$373.74M	N/A	N/A	70
IMRX Immuneering	2.2335 of 5 stars	$5.77 flat	$16.50 +186.0%	+128.9%	$373.32M	N/A	N/A	60	Analyst Forecast
PALI Palisade Bio	1.6857 of 5 stars	$2.12 flat	$10.20 +381.1%	+144.7%	$367.99M	$250K	N/A	10
PBYI Puma Biotechnology	1.2395 of 5 stars	$7.17 flat	N/A	+112.2%	$364.95M	$228.40M	14.94	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNTX) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rein Therapeutics (RNTX) Competitors

RNTX vs. AVIR, IMRX, PALI, PBYI, and GLSI

How does Rein Therapeutics compare to Atea Pharmaceuticals?

Summary

How does Rein Therapeutics compare to Immuneering?

Summary

How does Rein Therapeutics compare to Palisade Bio?

Summary

How does Rein Therapeutics compare to Puma Biotechnology?

Summary

How does Rein Therapeutics compare to Greenwich LifeSciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rein Therapeutics (RNTX) Competitors

RNTX vs. AVIR, IMRX, PALI, PBYI, and GLSI

How does Rein Therapeutics compare to Atea Pharmaceuticals?

Which has more risk & volatility, AVIR or RNTX?

Which has preferable earnings and valuation, AVIR or RNTX?

Is AVIR or RNTX more profitable?

Do institutionals and insiders believe in AVIR or RNTX?

Do analysts recommend AVIR or RNTX?

Does the media refer more to AVIR or RNTX?

Summary

How does Rein Therapeutics compare to Immuneering?

Which has more volatility & risk, RNTX or IMRX?

Does the media prefer RNTX or IMRX?

Which has preferable valuation & earnings, RNTX or IMRX?

Do analysts rate RNTX or IMRX?

Is RNTX or IMRX more profitable?

Do insiders & institutionals hold more shares of RNTX or IMRX?

Summary

How does Rein Therapeutics compare to Palisade Bio?

Do analysts rate RNTX or PALI?

Does the media favor RNTX or PALI?

Is RNTX or PALI more profitable?

Which has stronger earnings and valuation, RNTX or PALI?

Which has more volatility and risk, RNTX or PALI?

Do insiders and institutionals hold more shares of RNTX or PALI?

Summary

How does Rein Therapeutics compare to Puma Biotechnology?

Which has stronger valuation & earnings, RNTX or PBYI?

Does the media prefer RNTX or PBYI?

Do analysts prefer RNTX or PBYI?

Is RNTX or PBYI more profitable?

Which has more risk and volatility, RNTX or PBYI?

Do insiders & institutionals hold more shares of RNTX or PBYI?

Summary

How does Rein Therapeutics compare to Greenwich LifeSciences?

Is RNTX or GLSI more profitable?

Do institutionals & insiders hold more shares of RNTX or GLSI?

Do analysts rate RNTX or GLSI?

Which has more volatility and risk, RNTX or GLSI?

Which has higher valuation & earnings, RNTX or GLSI?

Does the media prefer RNTX or GLSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools